Tag: mCRPC treatment options

Home / mCRPC treatment options

Categories

The FDA has broadened the indication for Pluvicto to include metastatic castration-resistant prostate cancer

On March 28, 2025, the Food and Drug Administration expanded the use of lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) to include adults with prostate-specific ...
mcrpc-treatment-options

Scan the code